Drugs / LMP400
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01794104 | Feb 2013 → May 2016 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01051635 | Jan 2010 → Jun 2017 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-11-06 | Allarity Therapeutics | Results Presentation of use of DRP(TM) in Top1 at AACR congress in Boston allarity.com ↗
Data from this scientific collaboration shows that LMP400 has topoisomerase 1 inhibitory activity, and that colon cancer and breast cancer could be target for clinical trials. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-11-06 | Allarity Therapeutics | Presentation of use of DRP(TM) in Top1 at AACR congress in Boston allarity.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01794104 ↗ |
| Known as | NSC 743400 | “A first-in-human Phase I study conducted at the NCI of the indenoisoquinoline LMP400 (NSC 743400) on a QD x 5 q28 schedule in patients with refractory solid tumors and...” NCT01794104 ↗1“LMP400 (NSC 743400) and LMP776 (NSC 725776) are indenoisoquinolines that have not been given to cancer patients before.” NCT01051635 ↗ |
| Action | Inhibit | “Top1 inhibitors such as LMP400 are potent anticancer agents” NCT01794104 ↗ |
| Route | Intravenous | “LMP400 administered IV daily for 5 days per dose escalation table.” NCT01051635 ↗ |